REVISIONES, METAANÁLISIS Y ENSAYOS

Silimarina como potencial agente hepatoprotector

Silymarin as potential hepatoprotective agent 

Rev Cadena Cereb 2019; 3(2).jpg

María Adelina Jiménez-Arellanes (1).

Afiliaciones:

  1. Unidad de Investigación Médica en Farmacología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México.

 

Correspondencia:

María Adelina Jiménez-Arellanes: adelinajim08@prodigy.net.mx

2019 © Jiménez-Arellanes MA. Silimarina como potencial agente hepatoprotector.

Esta obra se distribuye bajo una Licencia Creative Commons Reconocimiento-NoComercial 4.0 Internacional (CC BY-NC).

Volumen 3, Número 2

Julio-Diciembre 2019

Páginas 60-70

Visitantes de este artículo

Ver artículo en: REDIB     Zenodo

https://doi.org/10.5281/zenodo.3903937

Conflictos de Interés: La autora declara que no tiene conflictos de interés.

Fuentes de Financiamiento: Ninguna.

Sugerencia de cita: Jiménez-Arellanes MA. Silimarina como potencial agente hepatoprotector. Rev Cadena Cereb. 2019; 3(2): 60-70.

Recibido: 17/01/2020.

Aceptado: 02/05/2020.

RESUMEN

El hígado es el encargado de la homeostasis y de metabolizar diversas sustancias (endógenas y exógenas, incluyendo fármacos), las cuales al metabolizarse generan metabolitos más tóxicos y/o reactivos; por esto el hígado es más susceptible de sufrir algún daño como cirrosis, esteatosis y/o hasta hepatocarcinoma. El ser humano ha empleado diversas plantas medicinales (PM) desde tiempos ancestrales para tratar sus padecimientos, enfermedades y dolencias; entre ellas esta Sylibum marianum. Planta utilizada en el tratamiento de ictericia u otras enfermedades biliares; así como, en terapia de apoyo en la intoxicación por hongos y en el tratamiento de diversas enfermedades hepáticas. A partir de esta especie medicinal se obtiene la silimarina (mezcla de flavonoides), esta sustancia tiene importante efecto antioxidante, también tiene diversas actividades biológicas como hepatoprotector. Esta actividad se ha demostrado mediante diversos estudios preclínicos y clínicos.

Palabras Clave: Silimarina, hepatotoxicidad, silibina, hepatoprotector, nefroprotector.

ABSTRACT

The liver is in charge of homeostasis and of metabolizing various substances (endogenous and exogenous, including drugs), many of which, when metabolized, generate more toxic and/or reactive metabolites, for this reason, the liver is more susceptible to suffer some damage such as cirrhosis, steatosis and/or even hepatocarcinoma. The humanity has been used several medicinal plants (PM) since ancestral times to treat their ailments, diseases and ailments; among them is Sylibum marianum, that has been used in the treatment of jaundice or other biliary diseases; as well as, in supportive therapy in fungal poisoning and in the treatment of some liver diseases. From this medicinal plant has been obtained sylimarin (flavonoids mixture), this substance has significative antioxidant effect, also has some biological activities such as hepatoprotective. This activity has been demonstrated by preclinical and clinical trials.

Key words: Silymarin, hepatotoxicity, silibin, hepatoprotective, nephroprotective.

REFERENCIAS

  1. Vargas-Mendoza N, Madrigal-Santillán E, MoralesGonzález Á, Esquivel-Soto J, Esquivel-Chirino C, GarcíaLuna y González-Rubio M, et al. Hepatoprotective effect of silymarin. World J Hepatol. 2014; 6(3): 144-9. DOI: 10.4254/wjh.v6.i3.144

  2. Hoekstra LT, de Graaf W, Nibourg GAA, Heger M, Bennink RJ, Stieger B, et al. Physiological and Biochemical Basis of Clinical Liver Function Tests. Annals Surg. 2013; 257(1): 2736. DOI: 10.1097/sla.0b013e31825d5d47

  3. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, et al. Global Trends and Predictions in Hepatocellular Carcinoma Mortality. J Hepatol. 2017; 67(2): 302 -9. DOI: 10.1016/j.jhep.2017.03.011

  4. Global Hepatitis Report 2017. 1a Edición. Geneva: World Health Organization; 2017. Disponible en: http://apps.who.int/iris/bitstream/handle/10665/255016/9789241 565455-eng.pdf

  5. Rowe IA. Lessons from Epidemiology: The Burden of Liver Disease. Dig Dis. 2017; 35(4): 304-9. DOI: 10.1159/000456580

  6. Jiménez-Arellanes MA, Gutiérrez-Rebolledo GA, MeckesFischer M, León-Díaz R. Medical plant extracts and natural compounds with a hepatoprotective effect against damage caused by antitubercular drugs: A review. Asian Pac J Trop Med. 2016; 9(12): 1141-9. DOI: 10.1016/ j.apjtm.2016.10.010

  7. Damian D. Efecto hepatoprotector del extracto orgánico de las partes aéreas de Cnidoscolus chayamansa. Tesis de Maestría. Tecnológico de Estudios Superiores de Ecatepec. 2018. 

  8. Salwe KJ, Mirunalini R, Mano J, Manimekalai K. Hepatoprotective and antioxidant activity of Murraya Koenigii leaves extract against paracetamol induced hepatotoxicity in Rats. Int J Bas Clin Pharmacol. 2017; 6(6): 1274-81. DOI: 10.18203/2319-2003.ijbcp20172044

  9. Asadi-Samani M, Kafash-Farkhad N, Azimi N, Fasihi A, Alinia-Ahandani E, Rafieian-Kopaei M. Medicinal plants with hepatoprotective activity in Iranian folk medicine. Asian Pac J Trop Biomed. 2015; 5(2): 146-57. DOI: 10.1016/ S2221-1691(15)30159-3

  10. Bailón-Martínez D, Jiménez-Arellanes MA. Efecto hepatoprotector de compuestos naturales, productos biológicos y extractos de plantas medicinales contra el daño provocado por fármacos antituberculosos (Parte II). Rev Mex Cienc Farm. 2018; 49(3): 1-31.

  11. Quezada SM, Briscoe J, Cross RK. Complementary and Alternative Medicine. Inflamm Bowel Dis. 2016; 22(6): 1523-30. DOI: 10.1097/MIB.0000000000000761 

  12. Azwanida NN. A Review on the Extraction Methods Use in Medicinal Plants, Principle, Strength and Limitation. Med Arom Plants. 2015; 4(3): 1000196. DOI: 10.4172/21670412.1000196

  13. Comelli MC, Mengs U, Schneider C, Prosdocimi M. Toward the Definition of the Mechanism of Action of Silymarin: Activities Related to Cellular Protection from Toxic Damage Induced by Chemotherapy. Integr Cancer Ther. 2007; 6 (2): 120-9. DOI: 10.1177/1534735407302349

  14. Mastron J, Siveen K, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: A systematic, comprehensive and crtical review. Anti-cancer Drugs. 2015; 26(5): 475-86. DOI: 10.1097/cad.0000000000000211

  15. Kumar T, Larokar YK, Iyer SK, Kumar A, Tripathi DK. Phytochemistry and Pharmacological Activities of Silybum marianum: A Review. Int J Pharm Phytopharm Res. 8677; 7(9): 784 -33. Disponible en: https://www.academia.edu/2470494/ Phytochemistry_and_Pharmacological_Activities_of_Sily bum_marianum_A_Review

  16. Hellerbrand C, Schattenberg JM, Peterburs P, Lechner A, Brignoli R. The potential of silymarin for the treatment of hepatic disorders. Clin Phytosci. 2016; 2(7): 1-14. DOI: 10.1186/s40816-016-0019-2

  17. Kawaguchi-Suzuki M, Frye RF, Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, et al. The Effects of Milk Thistle (Silybum marianum) on Human Cytochrome P894 Activity. Drug Metab Dispos. 2014; 42(10): 1611-6. DOI: 10.1124/ dmd.114.057232

  18. Ferenci P. Silymarin in the treatment of liver diseases: What is the clinical evidence? Clin Liv Dis (Hoboken). 2016; 7(1): 8-10. DOI: 10.1002/cld.522

  19. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006; 124(5): 491-504. Disponible en: http://www.ijmr.org.in/article.asp?issn=09715916;year=2013;volume=137;issue=2;spage=423;epage=436 ;aulast=Pradhan;type=0

  20. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavonoid, Silibinin, Inhibits Proliferation and Promotes Cell-Cycle Arrest of Human Colon Cancer. J Surg Res. 2007; 143(1), 58-65. DOI: 10.1016/j.jss.2007.03.080 

  21. Jahan S, Khan M, Imran S, Sair M. The hepatoprotective role of Silymarin in isoniazid induced liver damage of rabbits. J Pak Med Assoc. 2015; 65(6): 620-2. Disponible en: https://jpma.org.pk/article-details/7375?article_id=7375

  22. Panchabhai TS, Ambarkhane SV, Joshi AS, Samant BD, Rege NN.  Protective Effect of Tinospora cordifolia, Phyllanthus emblica and Their Combination Against Antitubercular Drugs Induced Hepatic Damage: An Experimental Study. Phytother Res. 2008; 22(5): 646-50. DOI: 10.1002/ptr.2356

  23. Clichici S, Olteanu D, Nagy A, Oros A, Filip A, Mircea PA. Silymarin Inhibits the Progression of Fibrosis in the Early Stages of Liver Injury in CCl4-Treated Rats. J Med Food. 2015; 18(3): 290-8. DOI: 10.1089/jmf.2013.0179

  24. Hermenean A, Stan M, Ardelean A, Pilat L, Mihali CV, Popescu C, et al. Antioxidant and hepatoprotective activity of milk thistle (Silybum marianum L. Gaertn.) seed oil. Open Life Sci. 2015; 10(1): 225-36. DOI: 10.1515/biol-2015-0017

  25. Bektur NE, Sahin E, Baycu C, Unver G. Protective effects of silymarin against acetaminophen-induced hepatotoxicity and nephrotoxicity in mice. Toxicol Ind Health. 2013; 32(4): 589-600. DOI: 10.1177/0748233713502841

  26. Pari L, Kumar NA. Hepatoprotective Activity of Moringa oleifera on Antitubercular Drug-Induced Liver Damage in Rats. J Med Food. 2002; 5(3): 171-7. DOI: 10.1089/10966200260398206

  27. Domitrović R, Rashed K, Cvijanović O, Vladimir-Knežević S, Škoda M, Višnić A. Myricitrin exhibits antioxidant, antiinflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice. Chem Biol Interact. 2015; 230: 21 -9. DOI: 10.1016/j.cbi.2015.01.030

  28. Kim SH, Oh DS, Oh JY, Son TG, Yuk DY, Jung YS. Silymarin Prevents Restraint Stress-Induced Acute Liver Injury by Ameliorating Oxidative Stress and Reducing Inflammatory Response. Molecules. 2016; 21(4): 443. DOI: 10.3390/ molecules21040443

  29. Chen IS, Chen YC, Chou CH, Chuang RF, Sheen LY, Chiu CH. Hepatoprotection of silymarin against thioacetamideinduced chronic liver fibrosis. J Sci Food Agric. 2012; 92(7): 1441-7. DOI: 10.1002/jsfa.4723

  30. Jaswal A, Sinha N, Bhadauria M, Shrivastava S, Shukla S. Therapeutic potential of thymoquinone against antituberculosis drugs induced liver damage. Environ Toxicol Pharmacol. 2013; 36(3): 779-86. DOI: 10.1016/ j.etap.2013.07.010

  31. Rao CV, Rawat A, Singh AP, Singh A, Verma N. Hepatoprotective potential of ethanolic extract of Ziziphus oenoplia (L.) Mill roots against antitubercular drugs induced hepatotoxicity in experimental models. Asian Pac J Trop Med. 2012; 5(4): 283-8. DOI: 10.1016/s1995-7645(12)60040-6

  32. Sozmen M, Devrim AK, Tunca R, Bayezit M, Dag S, Essiz D. Protective effects of silymarin on fumonisin B1-induced hepatotoxicity in mice. J Vet Sci. 2014; 15(1): 51-60. DOI: 10.4142/jvs.2014.15.1.51

  33. Amin KA, Ahmed RR, Hozayen WG, Antar A. Renoprotective and Antioxidant Effects of Silymarin and Propolis on Diclofenac Sodium - Induced Renal Toxicity in Rats. Int J Pure Appl Biosci. 2017; 5(2): 31-42. DOI: 10.18782/23207051.2421

  34. Naik M, Chakraborty M, Ahmed R, Hamza S, Afsal M. Investigation of nefroprotective effect of silymarin against methotrexate and ifosfamide induced toxicity in rats. Int J Pharm Sci Res. 2015; 6(1): 174-9. Disponible en: https:// www.semanticscholar.org/paper/INVESTIGATION-OFNEPFROPROTECTIVE-EFFECT-OF-AGAINST-Naik-Chakrab orty/00d48d4f16d7cf6997b40c6f7ef4a667fc84b0af

  35. Gopi K, Reddy A, Jyothi K, Kumar B. Acetaminopheninduced Hepato- and Nephrotoxicity and Amelioration by Silymarin and Terminalia chebula in Rats. Toxicol Int. 2010; 17(2): 64-6. DOI: 10.4103/0971-6580.72672

  36. Shahbazi F, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. Potential renoprotective effects of silymarin against nephrotoxic drugs: A review of literature. J Pharm Pharmaceut Sci. 2012; 15(1): 112-23. DOI: 10.18433/J3F88S

  37. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant. 1996; 11(1): 55-62.

  38. Bailón D. Evaluación del efecto hepatoprotector de Rosmarinus officinalis y la mezcla de triterpenos contra el daño inducido por fármacos antituberculosos. Tesis Maestría. Instituto Politécnico Nacional. 2016.

  39. Rasool M, Iqbal J, Malik A, Ramzan HS, Qureshi MS, Asif M, et al. Hepatoprotective Effects of Silybum marianum (Silymarin) and Glycyrrhiza glabra (Glycyrrhizin) in Combination: A Possible Synergy. Evid Based Complement Alternat Med. 2014; 2014: 641597. DOI: 10.1155/2014/641597 

  40. Kim SH, Cheon HJ, Yun N, Oh ST, Shin E, Shim KS, et al. Protective Effect of a Mixture of Aloe vera and Silybum marianum Against Carbon Tetrachloride–Induced Acute Hepatotoxicity and Liver Fibrosis. J Pharmacol Sci. 2009; 109(1): 119-27. DOI: 10.1254/jphs.08189fp

  41. Jashitha M, Chakraborty M, Kamath JV. Effect of quercetin on hepatoprotective activity of silymarin against thioacetamide intoxicated rats. Int Res J Pharm. 2013; 4(7): 138-40. DOI: 10.7897/2230-8407.04730

  42. Giacomelli S, Gallo D, Apollonio P, Ferlini C, Distefano M, Morazzoni P, et al. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci. 2002; 70(12): 1447-59. DOI: 10.1016/ s0024-3205(01)01511-9

  43. Javed S, Ahsan W, Kohli K. Pharmacological influences of natural products as bioenhancers of silymarin against carbon tetrachloride-induced hepatotoxicity in rats. Clin Phytosci 2018; 4(1): 18. DOI: 10.1186/s40816-018-0079-6

  44. Nada SA, Gowife AMH, El-Denshary EES, Salama AA, Khali MG, Ahmed KA. Protective Effect of Grape Seed Extract and/or Silymarin Against Thioacetamide-induced Hepatic Fibrosis in Rats. J Liver. 2015; 4(2): 1-7. DOI: 10.4172/21670889.1000178

  45. Ghosh A, Ghosh T, Jain S. Silymarin-A review on the pharmacodynamics and bioavailability enhancement approaches. J Pharm Sci Techn. 2010; 2(10): 348-55. Disponible en: http://www.onlinepharmacytech.info/docs/vol2issue10/ JPST10-02-10-04.pdf

  46. Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 2015; 15(334): 1-7. DOI: 10.1186/s12906015-0861-7 

  47. Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 2015; 15(334): 1-7. DOI: 10.1186/s12906015-0861-7 

  48. Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006; 20(12): 1036-9. DOI: 10.1002/ ptr.1988

  49. Hagag A, Elgamsy M, El-Asy H, Mabrouk M. Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia. Mediterr J Hematol Infect Dis. 2016; 8(1): 1-9. DOI: 10.4084/MJHID.2016.043 

  50. Roozbeh J, Shahriyari B, Akmali M, Vessal G, Pakfetrat M, Jalali GAR, et al. Comparative Effects of Silymarin and Vitamin E Supplementation on Oxidative Stress Markers, and Hemoglobin Levels Among Patients on Hemodialysis. Ren Fail. 2011; 33(2): 118-23. DOI: 10.3109/0886022x.2010.541579

  51. Salmond S, George J, Strasser S, Byth K, Rawlinson B, Mori T, et al. Hep573 Study: A randomised, double-blind, placebo-controlled trial of silymarin alone and combined with antioxidants to improve liver function and quality of life in people with chronic hepatitis C. Aust J Herb Med. 2018; 30 (1): 12-25. 

  52. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, et al. Effect of Silymarin (Milk Thistle) on Liver Disease  in  Patients  with   Chronic   Hepatitis   C Unsuccessfully Treated with Interferon Therapy A Randomized Controlled Trial. JAMA. 2012; 308(3): 274-82. DOI: 10.1001/ jama.2012.8265 

  53. Tanamly M, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004; 36(11): 752-9. DOI: 10.1016/j.dld.2004.06.015 

Incluida en:

2016 - 2020 © Revista Cadena de Cerebros

e-ISSN: 2448-8178

Inauguración del sitio: 5 de agosto de 2016

Última actualización: 1 de julio de 2020

Revista Cadena de Cerebros es una revista independiente que nunca solicitará pagos para publicación, suscripción ni registro en la comunidad. Nuestro equipo editorial trabaja de forma gratuita.

¡Ayúdenos a seguir en línea!

Done a través de PayPal

Publicar un Artículo

Publique su trabajo en Revista Cadena de Cerebros. Consulte las Directrices para Autores y entérese de cómo arreglar su trabajo, la forma de envío, el proceso de evaluación y más.

Suscripción

La suscripción a Revista Cadena de Cerebros es gratuita y por tiempo ilimitado. Se le notificará cuando se publique un nuevo número, convocatorias, cursos, talleres, noticias, y más.